{
  "symbol": "BSX",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2109,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.166
  },
  "top_positive": [
    {
      "sent": "Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following: \u2022 decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels, \u2022 declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions, \u2022 decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations, \u2022 negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products, \u2022 the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products, \u2022 the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully, \u2022 changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and \u2022 increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.",
      "score": 0.9925
    },
    {
      "sent": "Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following: \u2022 decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels, \u2022 declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions, \u2022 decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations, \u2022 negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products, \u2022 the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products, \u2022 the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully, \u2022 changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and \u2022 increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.",
      "score": 0.9925
    },
    {
      "sent": "Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following: \u2022 decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels, \u2022 declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions, \u2022 decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations, \u2022 negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products, \u2022 the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products, \u2022 the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully, \u2022 changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and \u2022 increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.",
      "score": 0.9925
    }
  ],
  "top_negative": [
    {
      "sent": "Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims.",
      "score": -0.9578
    },
    {
      "sent": "Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other healthcare professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.",
      "score": -0.9559
    },
    {
      "sent": "Debt The following table presents the current and long-term portions of our total debt: As of (in millions) December 31, 2022 December 31, 2021 Current debt obligations $ 20 $ 261 Long-term debt 8,915 $ 8,804 Total debt $ 8,935 $ 9,065 The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis: As of (in millions) December 31, 2022 December 31, 2021 Fixed-rate debt instruments $ 8,910 $ 9,048 Variable rate debt instruments 25 17 Total debt $ 8,935 $ 9,065 As of December\u00a031, 2022, we were in compliance with the financial covenant required by the credit facilities described above.",
      "score": -0.9559
    }
  ],
  "forward_snippets": [
    "We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities.",
    "We believe that our execution of these strategic imperatives will help us deliver on our mission, drive innovation and increase value for our customers and employees, while strengthening our leadership position in the medical device industry and delivering profitable revenue growth.",
    "We expect to continue to invest in our core franchises and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets.",
    "We continue to develop digital tools and technologies that enable us to compete more effectively and deliver first class remote physician education, drive deeper patient engagement and increase digitally-enabled sales force productivity.",
    "This includes taking actions to combat discrimination and advancing equality and diversity, including through financial support of racial equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly."
  ]
}